Schedule of Pharmaceutical Benefits - 1 October 2022

PBAC

1 October 2022 - The October 2022 issue of the Schedule of Pharmaceutical Benefits is out and now in effect.

The October issue of the Schedule includes a number of major new/revised listings:

  • Avelumab (Bavencio) - new indication
  • Cedazuridine with decitabine (Inqovi) - new combination product
  • Enzalutamide (Xtandi) - new indication
  • Fremanezemab (Ajovy) - new formulation
  • Mecasermin (Increlix) - new medicine
  • Pembrolizumab (Keytruda) - new indication
  • Nivolumab (Opdivo) - new indication
  • Somatrogon (Ngenla) - new medicine
  • Trientine dihydrochloride (Trientine Waymade) - new medicine

Read Summary of PBS changes

Michael Wonder

Posted by:

Michael Wonder